+82-10-4499-3773

Palade BioTech

ADVANCING HUMAN HEALTH BY
BREAKTHROUGH THERAPEUTICS

We are a purpose-driven biotech company dedicated to transforming the lives of patients with life-threatening diseases who have no effective treatment options. Our mission is to deliver first-in-class, biology-driven therapies that overcome resistance mechanisms in both cancer and infectious diseases—addressing the most urgent and unmet medical needs.

With a bold vision to become a global leader in resistance-targeted therapeutics, we are pioneering curative solutions for drug-resistant, immunotherapy-refractory cancers and incurable viral threats, the areas of highest mortality and unmet need.

By focusing where others cannot, we aim to build a resilient, trusted company that delivers lasting impact to patients, partners, and the global healthcare community.

Get Started
About Us

Palade Bio: Who We Are

Created in 2021, Palade BioTech is a South Korean firm committed to finding innovative solutions for some of the world’s biggest medical challenges. We focus on developing new, innovative technologies using synthetic biology and synthetic chemistry tools to provide solutions. We focus on four key areas:

  • Oncolytic ADC drugs for drug-resistant cancers and for Keytruda-non-responsive cancers.
  • Next-generation cancer immunotherapy drugs
  • GPCR-target tumor microenvironment modulator drugs.
  • Virus therapeutic drugs.

Our mission is to create innovative treatments and solutions for the toughest biological challenges where no viable treatments currently exist. The Palade BioTech team is led by Bong-Kwan Han, a globally recognized pioneer in the field of medical synthetic biology, and an additional three members dedicated to finding solutions to some of the most pressing healthcare issues facing society.

Read More

Vision & Mission

Our Mission

Our mission is to transform outcomes for patients with life-threatening diseases who currently have no effective treatment options. We are committed to delivering first-in-class, biology-driven therapeutics that overcome resistance mechanisms in both cancer and infectious diseases, addressing the urgent unmet needs of patients left behind by existing therapies.Through scientific innovation, strategic partnerships, and rapid translational development, we aim to bring hope and survival to those fighting drug-resistant tumors and incurable viral infections such as HBV and Zika virus. 

Our Vision

We envision becoming a global biotech leader in resistance-targeted therapeutics, developing curative solutions for the hardest-to-treat cancers and untreatable viral diseases. Our integrated pipeline leverages our proprietary platforms to deliver breakthrough treatments across two high-impact domains of drug-resistant cancers and incurable viral infections. By focusing on diseases with high mortality, no effective treatments, and global impact, we aim to build a differentiated, resilient, and purpose-driven biotech company that creates lasting value for patients, partners, and shareholders.

Our Goals

We are building a differentiated biotech company with two ambitious and synergistic goals aimed at transforming care for patients with the fewest options:
1. Deliver Breakthrough Therapies for Drug-Resistant and Checkpoint-Inhibitor–Non-Responsive Cancers.
2. Pioneer Antiviral Therapies for Incurable Viral Threats. Our long-term goals: Establish a globally trusted pipeline company known for solving hard problems in oncology and virology. Drive impact-driven innovation for underserved patients globally, especially where existing treatments have failed.

What We Do

Innovative Solutions for Challenging Health Conditions

Drug-Resistant Cancer Treatment

Drug resistance in cancer is a major obstacle to successful treatment. Cancer cells can quickly evolve mechanisms to evade the effects of chemotherapy, targeted therapy, and immunotherapy. This leads to treatment failure, cancer progression, and, ultimately, decreased survival rates.

Read More

Next-Generation Immunocytokine Cancer Drugs

Cytokines (interferons and interleukins) regulate the function of T cells and immune cells like Keytruda. Cytokines were identified long before PD-1 and PD-L1, immune checkpoint regulators that Keytruda targets. 

Read More

GPCR-Target Tumor Microenvironment Modulator Drugs

MoSTT-CelSuR : Palade’s highly-efficient high-throughput screening technology for GPCR targets resolving the high frequent false positive read-out problem of the current screening methods.

Read More

Antiviral Drugs

There are 219 known human-infecting viruses Vaccines were developed for 16 human-infecting viruses Therapeutic drugs were developed for only 9 human-infecting viruses.

Read More

Making Real-World Impact Through Groundbreaking Research

What sets us apart?

We’re dedicated to scientific excellence, tackling the pressing challenges of our time, and shaping the future with groundbreaking research.

See our impact

Process

From Questions to Solutions

01

Ask big question

We start by identifying the most critical scientific questions and global challenges

02

Dive deep

With advanced tech and collaboration, we thoroughly explore every angle of our research

03

Real-World Application

We turn discoveries into practical solutions, partnering to bring science into action

What we’re working on right now

Innovations in Progress Uncovering Tomorrow's Solutions Today

We’re using AI for disease prediction and developing new treatments. Stay tuned!

Harnessing AI to Outsmart the Deadliest Cancers

We are leveraging advanced AI algorithms and molecular modeling to accelerate the discovery of breakthrough therapies for cancers that resist existing treatments—including checkpoint inhibitor–non-responsive tumors. Our AI-guided platform is unlocking novel therapeutic targets and biomarker strategies to overcome immune escape and tumor heterogeneity.

Where machine learning meets life-saving oncology.
0 %
Next-Generation Anti-Aging Therapeutics

Harnessing deep biology, epigenetics, and AI-enabled screening, we are developing innovative anti-aging solutions aimed at restoring cellular resilience, targeting senescence pathways, and extending healthspan. Our research is focused on systemic rejuvenation mechanisms and disease prevention at the molecular level.

Redefining Aging — One Molecule at a Time.
0 %
Combating Superbugs with AI-Designed Therapeutics

We’re addressing the global crisis of antibiotic resistance by developing next-generation antimicrobial agents using AI-driven design and synthetic biology. Our goal is to create smart, highly selective therapeutics that target resistant pathogens without disrupting the microbiome—offering powerful tools against life-threatening infections.

Fighting the Unbeatable — Smarter, Faster, Stronger.
0 %
What we’re working on right now

Innovations in Progress Uncovering Tomorrow's Solutions Today

We’re using AI for disease prediction and developing new treatments. Stay tuned!

Disease prediction

Sustainability is key to the future. Our research dives deep into climate change solutions and biodiversity protection

Faster response time
0 %
Sustainable material

Exploring AI, robotics, and beyond, we’re at the cutting edge of tech that’s poised to revolutionize daily life

Less packaging plastic by 2025
0 %
Innovative treatments

Making science accessible through education initiatives and community engagement to inspire future innovators

Better quality of life
0 %

WHAT OUR CLIENT SAY

Testimonials

At the heart of our mission is a deep commitment to transforming lives through science. These voices—of industry leaders, clinicians, and investors—reflect the trust, excitement, and shared vision driving our journey forward.

“This company has identified two of the most urgent unmet needs in medicine—drug-resistant cancers and refractory age-related diseases—and is tackling them with a clear, innovative strategy. Their focus on drug development for drug-resistant cancers and immunotherapy-refractory cancers gives them a differentiated scientific and commercial edge.”
Jae-Jun KimLawyer & FMR CEO of KOSDAQ
Jae-Jun Kim
“As an investor, what excites me most is their ability to combine groundbreaking science with a disciplined strategy for partnerships and licensing. They are building a pipeline that is not only innovative but also highly translatable to real patient outcomes.”
Ji-Hwan ParkCEO, JNP Global Partners
Ji-Hwan Park
“They combine deep scientific expertise with practical drug development know-how. Their programs are designed not just to generate exciting science, but to create therapies that can move efficiently from lab to patients.”
Dr. Hsuan-Chung HoPharmaceutical scientist, Bristol Myers Squibb
Dr. Hsuan-Chung Ho

GET IN TOUCH WITH US

We are a purpose-driven biotech company dedicated to transforming the lives of patients with life-threatening diseases who have no effective treatment options. By focusing where others cannot, we aim to build a resilient, trusted company that delivers lasting impact to patients, partners, and the global healthcare community.

CONTACT US

With a bold vision to become a global leader in resistance-targeted therapeutics, we are pioneering curative solutions for drug-resistant, immunotherapy-refractory cancers and incurable viral threats, the areas of highest mortality and unmet need.

Facebook X-twitter Youtube
Program
Links
Contact